Comparative Pharmacology
Head-to-head clinical analysis: LIVTENCITY versus TYZEKA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIVTENCITY versus TYZEKA.
LIVTENCITY vs TYZEKA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
Telbivudine is a synthetic thymidine nucleoside analogue with activity against hepatitis B virus (HBV). It is phosphorylated intracellularly to the active triphosphate form, which competes with natural thymidine triphosphate for incorporation into viral DNA, causing chain termination and inhibition of HBV DNA polymerase (reverse transcriptase).
200 mg orally once daily with food.
600 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
Terminal elimination half-life is approximately 15 hours (range 12-20 hours) in patients with normal renal function; half-life is prolonged in renal impairment, requiring dose adjustment.
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal excretion accounts for approximately 60%.
Category C
Category C
Antiviral
Antiviral, Hepatitis B